HCSF Management’s Haemonetics HAE Stock Holding History

HCSF Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-92,000	Closed	-$2.97M	–	11
2015 Q3	$2.97M	Sell	92,000 -208,000	-69%	-$7.83M	3.14%	10
2015 Q2	$12.4M	Buy	300,000 +10,000	+3%	+$422K	10.38%	5
2015 Q1	$13M	Buy	290,000 +12,681	+5%	+$530K	11.58%	4
2014 Q4	$10.4M	Buy	+277,319	New	+$10.2M	9.52%	6

Other funds holding HAE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

WHG

Westwood Holdings Group Dallas, Texas $13.3B AUM 29.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

HCSF Management's HAE Position: Q4 2015 in Review

HCSF Management sold out of Haemonetics (HAE) in Q4 2015, closing a stake of 92,000 shares — an estimated $2.97M sold.

HCSF Management first reported a position in HAE in Q4 2014 and held it in 4 quarters. The position peaked at $13M in Q1 2015. 164 funds tracked by Wall St. Rank hold HAE as of Q4 2015.

HCSF Management reported no remaining Haemonetics position as of Q4 2015 after selling out during the quarter.
HCSF Management sold 92,000 Haemonetics shares in Q4 2015, an estimated $2.97M.
HCSF Management first reported a position in Haemonetics in Q4 2014 and held it in 4 quarters.
HCSF Management's Haemonetics position peaked at $13M in Q1 2015.
164 funds tracked by Wall St. Rank held Haemonetics as of Q4 2015.

Based on HCSF Management's 13F filing for Q4 2015, filed 26 Feb 2016.